Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AIM

AIM ImmunoTech Inc

Mar 06 • 04:00PM ET

0.6944

+0.0534 8.33 %

Healthcare • Biotechnology • USA • AMEX

Mar 06, 7:05 PMAIM ImmunoTech closes rights offering, raising approximately $1.8 million via Series G preferred and Class G warrants

Peers: JNJ LLY PFE AZN-D MRNA BMY GILD AMGN REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-20.14	Insider Own	4.17%	Shs Outstand	4.22M	Perf Week	-23.49%
Market Cap	2.93M	Forward P/E	-	EPS next Y	-4.33	Insider Trans	0.00%	Shs Float	4.04M	Perf Month	-34.18%
Enterprise Value	2.86M	PEG	-	EPS next Q	-0.94	Inst Own	2.51%	Short Float	3.54%	Perf Quarter	-50.35%
Income	-15.75M	P/S	26.64	EPS this Y	75.00%	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-71.51%
Sales	0.11M	P/B	-	EPS next Y	44.13%	ROA	-165.08%	Short Interest	0.14M	Perf YTD	-38.49%
Book/sh	-2.20	P/C	1.22	EPS next 5Y	-	ROE	-3138.91%	52W High	35.96 -98.07%	Perf Year	-94.82%
Cash/sh	0.57	P/FCF	-	EPS past 3/5Y	8.53% 34.59%	ROIC	-	52W Low	0.61 13.08%	Perf 3Y	-98.68%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.99% 3.96%	Gross Margin	-191.07%	Volatility	17.23% 20.92%	Perf 5Y	-99.66%
Dividend TTM	-	EV/Sales	26.00	EPS Y/Y TTM	57.35%	Oper. Margin	-12382.14%	ATR (14)	0.15	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	0.64	Sales Y/Y TTM	-41.05%	Profit Margin	-14062.50%	RSI (14)	34.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.64	EPS Q/Q	75.55%	SMA20	-27.08%	Beta	1.28	Target Price	21.98
Payout	-	Debt/Eq	-	Sales Q/Q	-25.71%	SMA50	-38.17%	Rel Volume	0.22	Prev Close	0.64
Employees	23	LT Debt/Eq	-	Earnings	Nov 14	SMA200	-79.73%	Avg Volume	1.42M	Price	0.69
IPO	Jul 15, 1996	Option/Short	No / No	EPS/Sales Surpr.	-61.03% -	Trades		Volume	318,360	Change	8.33%

Mar-06-26 07:00PM	AIM ImmunoTech Announces Closing of its Rights Offering (GlobeNewswire) +8.33%
Mar-04-26 09:00AM	AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million (GlobeNewswire)
Mar-02-26 09:00AM	AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire) -14.89%
Feb-27-26 09:00AM	AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering (GlobeNewswire) -8.32%
Feb-25-26 09:00AM	AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 (GlobeNewswire)
08:55AM	Loading…
Feb-23-26 08:55AM	AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
Feb-12-26 04:35PM	CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -6.36% +58.23%
08:55AM	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event (GlobeNewswire)
Feb-11-26 08:30AM	AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -13.51%
Feb-06-26 08:55AM	AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -7.32%
Feb-05-26 08:40AM	AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) +16.59%
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-27-26 04:35PM	AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire)
Jan-23-26 01:22PM	AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire) -5.16%
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:10PM	Loading…
Dec-30-25 05:10PM	AIM ImmunoTech Announces Stock Dividend (GlobeNewswire) -10.32%
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-10-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Dec-01-25 08:55AM	AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series (GlobeNewswire)
Nov-18-25 08:55AM	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program (GlobeNewswire) -7.64%
Nov-10-25 08:55AM	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire) -6.37%
Nov-04-25 09:05AM	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) -20.40%
Nov-03-25 08:55AM	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue (GlobeNewswire)
Oct-23-25 08:51AM	Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions (Zacks)
Oct-22-25 12:02PM	Bet On 5 Top-Ranked Stocks With Rising P/E (Zacks)
Oct-20-25 09:15AM	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit (GlobeNewswire)
Oct-10-25 12:00PM	All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy (Zacks)
Sep-25-25 08:45AM	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors (GlobeNewswire)
Sep-22-25 09:00AM	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth (GlobeNewswire) +6.16%
Sep-21-25 09:10AM	Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) (Insider Monkey)
11:00AM	Loading…
Sep-04-25 11:00AM	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland (GlobeNewswire)
Aug-21-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +8.47%
Aug-15-25 09:00AM	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-14-25 08:55AM	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-11-25 06:55PM	FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 09:00AM	AIM ImmunoTechs Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
09:00AM	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
Aug-04-25 09:00AM	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval (GlobeNewswire) +6.36%
Jul-31-25 09:00AM	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering (GlobeNewswire)
Jul-29-25 09:00AM	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -56.25%
Jul-28-25 09:00AM	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) -14.29%
Jul-02-25 08:55AM	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies (GlobeNewswire)
Jun-20-25 04:15PM	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements (GlobeNewswire) +10.96%
Jun-17-25 08:55AM	AIM ImmunoTech Resumes Trading on NYSE American (GlobeNewswire) +6.84%
Apr-07-25 01:26PM	AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market (GlobeNewswire) -57.53%
Apr-04-25 04:45PM	AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal (GlobeNewswire) -19.37%
Mar-27-25 08:05AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Apr 04 '25	Buy	0.06	41,000	2,583	1,899,029	Apr 07 03:42 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Apr 04 '25	Buy	0.09	500	44	401,762	Apr 04 05:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience